Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 51, Issue 9, Pages 3104-3110Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00341-07
Keywords
-
Categories
Funding
- NCRR NIH HHS [M01 RR000034, RR000034, M01 RR000095, RR00095] Funding Source: Medline
- NIAID NIH HHS [U01 AI069439, U01 AI038855, UM1 AI069439, AI069439, AI32775, AI068636, U01 AI038858, U01 AI032775, U01 AI068636, UM1 AI069474, AI38855, UM1 AI068636, AI38858, AI069474, AI68636, U01 AI069474] Funding Source: Medline
Ask authors/readers for more resources
The potent induction of hepatic cytochrome P450 3A isoforms by rifampin complicates therapy for coinfection with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis. We performed an open-label, single-arm study to assess the safety and pharmacokinetic interactions of the HIV protease inhibitor atazanavir coadministered with rifampin. Ten healthy HIV-negative subjects completed pharmacokinetic sampling at steady state while receiving 300 mg atazanavir every 12 111 without rifampin (period 1), 300 mg atazanavir every 12 h with 600 mg rifampin every 24 111 (period 2), and 400 mg atazanavir every 12 111 with 600 mg rifampin every 24 h (period 3). During period 1, the mean concentration of drug in serum at 12 h (C-12 h) was 811 ng/ml (range, 363 to 2,484 ng/ml) for atazanavir, similar to historic seronegative data for once-daily treatment with 300 mg atazanavir boosted with 100 mg ritonavir. During periods 2 and 3, the mean C-12 h values for atazanavir were 44 ng/ml (range, <25 to 187 ng/ml) and 113 ng/ml (range, 39 to 260 ng/ml), respectively, well below historic seronegative data for once-daily treatment with 400 mg atazanavir without ritonavir. Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available